Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder

View Full Paper
Ask AI
Bookmark
Share

Authors

WHWalter HanelThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteJBJonathan E. BrammerThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteLALapo AlinariThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Discussion

Loading...

Member takes

Implication

Phase Ib trial demonstrates safety and efficacy of epcoritamab in relapsed/refractory PTLD, suggesting improved outcomes.

Key Points

  • Assess the efficacy and safety of epcoritamab in patients with relapsed or refractory post-transplant lymphoproliferative disorder.
  • Prospective, multicenter, open-label phase Ib trial
  • Adult patients with relapsed/refractory B-cell PTLD following solid organ or bone marrow transplant
  • Epcoritamab administered with dose ramp-up and monitoring for toxicities
  • Demonstrated safety and clinical activity of epcoritamab in relapsed/refractory PTLD
  • Primary endpoint includes assessment of safety and determination of recommended phase II dose
  • Secondary endpoints include progression free survival and relationship of tumor microenvironment with treatment response

Cite This Study

Hanel et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e32fhttps://doi.org/10.1182/blood-2025-8240
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial2025
  2. 2Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).2024 · 14 citations
  3. 3Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial2025
  4. 4Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial2026
  5. 5Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T).2024 · 1 citations